What were Hester Biosciences Ltd's latest quarterly results?
Hester Biosciences Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +750.0% (stable)
- Revenue Growth YoY: +22.0%
- Operating Margin: 34.0% (volatile)
Hester Biosciences Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +54.1%Strong4w Streak
In , Hester Biosciences Ltd (Pharma - Animal) is outperforming Nifty 500 with +54.1% relative strength. Fundamentals: Strong. On a 4-week streak.
Hester Biosciences Ltd Key Facts
- PE Ratio
- 35.4x
- Market Cap
- ₹1,898 Cr
- PAT Growth YoY
- +750%
- Revenue Growth YoY
- +22%
- OPM
- 34.0%
- RS vs Nifty 500
- +54.1%
PE: Cycle BottomStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
Key Numbers
PAT Growth YoY
+750%
Stable
Revenue YoY
+22%
Stable
Operating Margin
34.0%
+1100 bps YoY
PE Ratio
35.4
Current Price
₹2,231
Dividend Yield
0.49%
Fundamental Score
67/100
Strong
3Y PAT CAGR
+27%
Market Cap
1.9K Cr
Valuation
Fairly Valued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Hester Biosciences Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +22% | +8% | Stable |
| PAT (Net Profit) | +750% | +27% | Stable |
| OPM | 34.0% | +1100 bps | Volatile |
Other Top Pharma - Animal Stocks Beating Nifty 500
Frequently Asked Questions: Hester Biosciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Hester Biosciences Ltd's profit growing or declining?
Hester Biosciences Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +750.0% (latest quarter)
- PAT Growth QoQ: +88.9% (sequential)
- 3-Year PAT CAGR: +26.7%
- Trend: Stable — consistent growth pattern
What is Hester Biosciences Ltd's revenue growth trend?
Hester Biosciences Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +22.0%
- Revenue Growth QoQ: +29.9% (sequential)
- 3-Year Revenue CAGR: +7.8%
How is Hester Biosciences Ltd's operating margin trending?
Hester Biosciences Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: +11.0% basis points
- OPM Change QoQ: +11.0% basis points
What is Hester Biosciences Ltd's 3-year profit and revenue CAGR?
Hester Biosciences Ltd's long-term compounding rates
- 3-Year Profit CAGR: +26.7%
- 3-Year Revenue CAGR: +7.8%
Is Hester Biosciences Ltd's growth accelerating or decelerating?
Hester Biosciences Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +118.2% bps
- Sequential Acceleration: +85.7% bps
What is Hester Biosciences Ltd's trailing twelve month (TTM) performance?
Hester Biosciences Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹57 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹332 Cr
- TTM Revenue Growth: +6.8% YoY
- TTM Operating Margin: 26.0%
Is Hester Biosciences Ltd overvalued or undervalued?
Hester Biosciences Ltd appears fairly valued based on our fair value analysis.
- Valuation Signal: Fairly Valued
- Current PE: 35.4x
- Price-to-Book: 5.3x
What is Hester Biosciences Ltd's current PE ratio?
Hester Biosciences Ltd's current PE ratio is 35.4x.
- Current PE: 35.4x
- Market Cap: 1.9K Cr
- Dividend Yield: 0.49%
How does Hester Biosciences Ltd's valuation compare to its history?
Hester Biosciences Ltd's current PE is 35.4x.
- Current PE: 35.4x
- Valuation Assessment: Fairly Valued
What is Hester Biosciences Ltd's price-to-book ratio?
Hester Biosciences Ltd's price-to-book ratio is 5.3x.
- Price-to-Book (P/B): 5.3x
- Book Value per Share: ₹423
- Current Price: ₹2231
Is Hester Biosciences Ltd a fundamentally strong company?
Hester Biosciences Ltd is rated Strong with a fundamental score of 66.64/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +22.0% (10% weight)
- PAT Growth YoY: +750.0% (10% weight)
- PAT Growth QoQ: +88.9% (10% weight)
- Margins stable (10% weight)
Is Hester Biosciences Ltd debt free?
Hester Biosciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹195 Cr
What is Hester Biosciences Ltd's return on equity (ROE) and ROCE?
Hester Biosciences Ltd's return ratios over recent years
- FY2024: ROCE 9.0%
- FY2025: ROCE 10.0%
- FY2026: ROCE 15.0%
Is Hester Biosciences Ltd's cash flow positive?
Hester Biosciences Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹64 Cr
- Free Cash Flow (FCF): ₹46 Cr
- CFO/PAT Ratio: 112% (strong cash conversion)
What is Hester Biosciences Ltd's dividend yield?
Hester Biosciences Ltd's current dividend yield is 0.49%.
- Dividend Yield: 0.49%
- Current Price: ₹2231
Who holds Hester Biosciences Ltd shares — promoters, FII, DII?
Hester Biosciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 53.7%
- FII (Foreign): 0.4%
- DII (Domestic): 0.0%
- Public: 45.9%
Is promoter holding increasing or decreasing in Hester Biosciences Ltd?
Hester Biosciences Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 53.7% (Mar 2026)
- Previous Quarter: 53.7% (Dec 2025)
- Change: 0.00% (stable)
How long has Hester Biosciences Ltd been outperforming Nifty 500?
Hester Biosciences Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Hester Biosciences Ltd a new momentum entry or an established outperformer?
Hester Biosciences Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Is Hester Biosciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Hester Biosciences Ltd may be worth studying
- Earnings growing at +750.0% YoY
- Cash flow is positive — CFO ₹64 Cr
What is the investment thesis for Hester Biosciences Ltd?
Hester Biosciences Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +22.0% YoY
What is the future outlook for Hester Biosciences Ltd?
Hester Biosciences Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Fairly Valued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.